Stock Events

Stock Events

vTv Therapeutics 

$32.90
26
+$1.42+4.49% Wednesday 20:00
+$0.00+0%Wednesday 23:30After hours

Statistics

Day High
33.01
Day Low
32.86
52W High
44
52W Low
14.55
Volume
796
Avg. Volume
-
Mkt Cap
130.06M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.15
-0.21
0.72
1.65
Expected EPS
-1.146
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-26.97MNet Income

Analyst Ratings

47.67Average Price Target
The highest estimate is 57.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VTVT. It's not an investment recommendation.
Tesla
7
TSLA
Palantir Technologies
7
PLTR
PayPal
7
PYPL
Amazon
6
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap31B
Biogen has a strong portfolio in neurodegenerative diseases, including Alzheimer's, making it a direct competitor to vTv Therapeutics.
Axsome Therapeutics
AXSM
Mkt Cap11.19B
Axsome Therapeutics works on central nervous system disorders, including Alzheimer's disease, competing in the same space as vTv Therapeutics.
AnaptysBio
ANAB
Mkt Cap1.73B
AnaptysBio is involved in developing therapeutic antibodies for inflammatory diseases, which could overlap with vTv Therapeutics' work on conditions like psoriasis.
Acadia Pharmaceuticals
ACAD
Mkt Cap4.87B
ACADIA Pharmaceuticals focuses on central nervous system disorders, posing competition to vTv Therapeutics' Alzheimer's disease treatments.
Alkermes
ALKS
Mkt Cap8.23B
Alkermes works on central nervous system diseases, including treatments for schizophrenia and bipolar I disorder, areas that could compete with vTv Therapeutics' focus.
AMGEN
AMGN
Mkt Cap224.63B
Amgen's broad focus on innovative therapeutics includes work on neurodegenerative diseases, making it a competitor in the Alzheimer's space.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie has a diverse portfolio that includes neuroscience, directly competing with vTv Therapeutics in the Alzheimer's and cognitive impairment market.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly has a strong presence in Alzheimer's disease research and treatment, directly competing with vTv Therapeutics.
Pfizer
PFE
Mkt Cap152.69B
Pfizer has a wide range of therapeutic areas, including Alzheimer's disease research, making it a competitor to vTv Therapeutics.

About

vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
Show more...
CEO
Paul J. Sekhri
Employees
26
Country
United States
ISIN
US9183852048
WKN
000A3EWXG

Listings

STU
DE
5VT0.STU
MU
DE
5VT.MU
STU
DE
5VT.STU
MU
DE
5VT0.MU

0 Comments

Share your thoughts

FAQ

What is vTv Therapeutics stock price today?▼
The current price of VTVT is $32.90 USD — it has increased by +4.49% in the past 24 hours. Watch vTv Therapeutics stock price performance more closely on the chart.
What is vTv Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange vTv Therapeutics stocks are traded under the ticker VTVT.
Is vTv Therapeutics stock price growing?▼
VTVT stock has risen by +6.63% compared to the previous week, the month change is a +1.59% rise, over the last year vTv Therapeutics has showed a +119.3% increase.
What is vTv Therapeutics market cap?▼
Today vTv Therapeutics has the market capitalization of 130.06M
When is the next vTv Therapeutics earnings date?▼
vTv Therapeutics is going to release the next earnings report on November 05, 2026.
What were vTv Therapeutics earnings last quarter?▼
VTVT earnings for the last quarter are -1.05 USD per share, whereas the estimation was -0.97 USD resulting in a -8.25% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is vTv Therapeutics revenue for the last year?▼
vTv Therapeutics revenue for the last year amounts to 0 USD.
What is vTv Therapeutics net income for the last year?▼
VTVT net income for the last year is -26.97M USD.
How many employees does vTv Therapeutics have?▼
As of August 20, 2026, the company has 26 employees.
In which sector is vTv Therapeutics located?▼
vTv Therapeutics operates in the Health & Wellness sector.
When did vTv Therapeutics complete a stock split?▼
The last stock split for vTv Therapeutics was on November 21, 2023 with a ratio of 1:40.
Where is vTv Therapeutics headquartered?▼
vTv Therapeutics is headquartered in HIGH POINT, United States.